NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor

This page covers all NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein.

Targets

HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein

Phase 3 pipeline (1)

• Sofosbuvir and Daklatasuvir · Sherief Abd-Elsalam · Infectious Disease
  Sofosbuvir and Daklatasuvir work together to inhibit the HCV NS5B RNA-dependent RNA polymerase and NS5A protein, respectively, to treat hepatitis C virus infection.

Patent intelligence

• ns5b rna dependent rna polymerase inhibitor and ns5a inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates